MedPath

Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

Phase 3
Completed
Conditions
Lumbosacral Radiculopathy
Interventions
Combination Product: Clonidine Micropellets
Other: Sham
Registration Number
NCT03727100
Lead Sponsor
Sollis Therapeutics, Inc.
Brief Summary

This study will evaluate the safety and effectiveness of a new pain medication in development, clonidine micropellet. Participants will receive a single injection of either clonidine micropellet or sham injection for the treatment of low back and leg pain from sciatica.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
207
Inclusion Criteria
  1. Be between 18 and 70 years of age (inclusive) at time the Informed Consent Form (ICF) is signed.
  2. Diagnosis of unilateral radicular leg pain.
  3. Women of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to procedure and commit to adequate birth control during the the study.
  4. Understands the purpose and any risks associated with the procedure required for the study and is willing to participate in the study.
  5. Agrees to follow study-specific medication requirements.
  6. Be able to read, write, understand, and complete study-related tasks, and adequately communicate in English.
  7. Subject must have failed at least one conservative therapy in two different categories.

Main

Exclusion Criteria
  1. Medical condition or radiographic evidence that, in the Investigator's opinion, could adversely impact study outcomes.
  2. Received an lumbar epidural steroid injection, nerve block or similar procedure during the 4 weeks prior to Screening.
  3. Female subjects who are pregnant or breastfeeding.
  4. History of lumbar surgery.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Clonidine MicropelletsClonidine Micropelletssingle dose injection into the lumbar epidural space
Sham ControlShamnon-epidural needle placement
Primary Outcome Measures
NameTimeMethod
Pain Intensity Difference (PID) for the average pain Numeric Rating Scale (NRS) from baseline to D30 in radicular leg painBaseline to day 60

Difference in average pain score, using a scale of 0-10 with 0 no pain and 10 worst possible pain, from baseline to day 30.

Secondary Outcome Measures
NameTimeMethod
Change in Oswestry Disability Index (ODI) scoreBaseline to day 30

6 categories of 10 question, each question is scored from 0-5 (minimum to maximum). The scores range from 0-100% with lower scores meaning less disability.

Change in Numeric Rating Scale (NRS) leg pain 24 hrs post injection.1 day post injection

Difference in average pain score, using a scale of 0-10 with 0 no pain and 10 worst possible pain, from injection to 24 hrs post injection.

Percent of subjects with significant improvement in painBaseline to day 30

50 percent improvement in pain from baseline to day 30

Difference in Rescue medication consumptionBaseline to day 30

Consumption from baseline through day 30

Trial Locations

Locations (32)

Sollis Clinical Study Site 35

🇺🇸

Fort Lauderdale, Florida, United States

Sollis Clinical Study Site 14

🇺🇸

Kansas City, Kansas, United States

Sollis Clinical Study Site 16

🇺🇸

Boston, Massachusetts, United States

Sollis Clinical Study Site 38

🇺🇸

Miami, Florida, United States

Sollis Clinical Study Site 22

🇺🇸

San Antonio, Texas, United States

Sollis Clinical Study Site 47

🇺🇸

Salt Lake City, Utah, United States

Sollis Clinical Study Site 36

🇺🇸

Mobile, Alabama, United States

Sollis Clinical Study Site 21

🇺🇸

Cleveland, Ohio, United States

Sollis Clinical Study Site 43

🇺🇸

The Woodlands, Texas, United States

Sollis Clinical Study Site 31

🇺🇸

Rochester, New York, United States

Sollis Clinical Study Site 19

🇺🇸

Edmond, Oklahoma, United States

Sollis Clinical Study Site 40

🇺🇸

Tucson, Arizona, United States

Sollis Clinical Study Site 33

🇺🇸

Cleveland, Ohio, United States

Sollis Clinical Study Site 46

🇺🇸

Eugene, Oregon, United States

Sollis Clinical Study Site 25

🇺🇸

Albany, New York, United States

Sollis Clinical Study Site 20

🇺🇸

Tyler, Texas, United States

Sollis Clinical Study Site 34

🇺🇸

Houston, Texas, United States

Sollis Clinical Study Site #41

🇺🇸

Phoenix, Arizona, United States

Sollis Clinical Study Site 29

🇺🇸

Scottsdale, Arizona, United States

Sollis Clinical Study Site 30

🇺🇸

Washington, District of Columbia, United States

Sollis Clinical Study Site 13

🇺🇸

Chicago, Illinois, United States

Sollis Clinical Study Site 28

🇺🇸

Santa Rosa, California, United States

Sollis Clinical Study Site 12

🇺🇸

Bloomington, Illinois, United States

Sollis Clinical Study Site 49

🇺🇸

Rancho Mirage, California, United States

Sollis Clinical Study Site

🇺🇸

Dallas, Texas, United States

Sollis Clinical Study Site 15

🇺🇸

Brookline, Massachusetts, United States

Sollis Clinical Study Site 17

🇺🇸

Shrewsbury, New Jersey, United States

Sollis Clinical Study Site 10

🇺🇸

Edgewood, Kentucky, United States

Sollis Clinical Study Site 23

🇺🇸

Morgantown, West Virginia, United States

Sollis Clinical Study Site 27

🇺🇸

Madison, Wisconsin, United States

Sollis Clinical Study Site #44

🇺🇸

Phoenix, Arizona, United States

Sollis Clinical Study Site 18

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath